Guardant Health (NASDAQ:GH) posted its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.25, Briefing.com reports. The firm had revenue of $60.85 million for the quarter, compared to analysts’ expectations of $45.40 million. Guardant Health had a negative return on equity of 22.93% and a negative net margin of 60.08%. The company’s quarterly revenue was up 180.4% compared to the same quarter last year. During the same quarter last year, the business earned ($1.94) EPS.
GH stock traded up $7.69 during trading hours on Friday, hitting $71.89. 3,794,600 shares of the stock were exchanged, compared to its average volume of 1,093,573. The company has a 50-day simple moving average of $66.52 and a two-hundred day simple moving average of $80.32. Guardant Health has a 12 month low of $31.06 and a 12 month high of $112.21. The firm has a market capitalization of $6.32 billion and a P/E ratio of -25.68.
Several research analysts have weighed in on the company. Canaccord Genuity reiterated a “buy” rating and set a $125.00 price objective on shares of Guardant Health in a research report on Friday. Zacks Investment Research cut Guardant Health from a “buy” rating to a “hold” rating in a research report on Thursday. JPMorgan Chase & Co. increased their price objective on Guardant Health from $90.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Cowen set a $110.00 price objective on Guardant Health and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, ValuEngine upgraded Guardant Health from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $104.40.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Featured Article: What is the yield curve?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.